Genzyme Corp

Genzyme — Investor Day (May 2007)

9 slides from Genzyme's investor day presentation, May 16, 2007

  1. Slide 1: Genzyme Corporation 2007 Analyst and Investor Meeting

    May 16, 2007 Boston, MA Genzyme Corporation 2007 Analyst and Investor Meeting

  2. Slide 2: Forward-Looking Statements

    Total Treated LSD Patients 0 2,000 4,000 6Forward-Looking Statements Our presentations today contain forward-looking statements regarding our financial outlook and business strategies, including without limitation, statements regarding: our projected product development, regulatory filing and action

  3. Slide 3: Total Treated LSD Patients

    Total Treated LSD Patients 0 2,000 4,000 6,000 8,000 10,000 12,000 14,000 2005 2006 2007E 2008E 2009E 2010E 2011E 2012E

  4. Slide 4: WW LSD Business Unit Revenue 2000 - 2007

    WW LSD Business Unit Revenue 2000 - 2007 Includes 100% of Aldurazyme revenues, revenues recorded by Genzyme-BioMarin Joint Venture CAGR = 18.7% $Millions $0 $250 $500 $750 $1,000 $1,250 $1,500 $1,750 $2,000 2000 2001 2002 2003 2004 2005 2006 2007E Other MZ AZ FZ CZ $539 $578 $647 $833 $1,094 $1,321

  5. Slide 5: LSD Revenue (Excluding Aldurazyme)

    LSD Revenue (Excluding Aldurazyme) $Millions $0 $500 $1,000 $1,500 $2,000 $2,500 2002 2003 2004 2005 2006 2007E 2008E 2009E 2010E 2011E 2012E $1.4B $2.4B

  6. Slide 6: WW Sepra Family Revenues Expected to Exceed $100M in 2007

    WW Sepra® Family Revenues Expected to Exceed $100M in 2007 Revenue ($M) $29 $39 $48 $62 $68 $85 > $100 CAGR 2001 – 2006: 24% 0 20 40 60 80 100 120 2001 2003 2005 2007E

  7. Slide 7: MOZOBIL and CXCR4/CCR5 Mechanism May Provide Significant Opportunities

    MOZOBIL and CXCR4/CCR5 Mechanism May Provide Significant Opportunities Stem Cell Transplant 55K pts Spectrum of development window Near-term Long-term Chemo- Sensitization 75K pts Development Risk Acute CV Conditions 1.5B pts HIV 1.2M pts Renal Ischemic Disease 1.3M pts Oncology Metastasis 2.3M pts

  8. Slide 8: Genzyme Hematology/Oncology Franchise Revenue

    $555M $1,040M Worldwide Revenue in $Millions Notes: (1) Cerezyme hematology/oncology revenue is approximately one-third of total Cerezyme revenue 2006 total Cerezyme revenue was $1.07 billion, estimated for 2010 at $1.1 billion (2)Campath and Clolar “revenue” reflects end-user sales of each, not rev

  9. Slide 9: Renal: What Can This Be?

    Renal: What Can This Be? $ Millions 0 100 200 300 400 500 600 700 800 900 1,000 1,100 1,200 1999 2000 2001 2002 2003 2004 2005 2006 2007E 2008E 2009E 2010E 2011E Sevelamer Hectorol

Genzyme — Investor Day (May 2007) on 6ix